Nivolumab and ipilimumab (renal cell carcinoma): Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL; Injection concentrate for I.V. infusion 100 mg in 10 mL; Ipilimumab: Injection concentrate for I.V. infusion 50 mg in 10 mL; Injection concentrate for I.V. infusion 200 mg in 40 mL; Opdivo® and Yervoy®

Page last updated: 15 March 2019

• Public Summary Document (PSD) July 2018 PBAC Meeting - (PDF 191 KB)
• Public Summary Document (PSD) July 2018 PBAC Meeting - (Word 77 KB)